A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors (Q44100795)

29 November 2017

title

A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors (English)

1 reference

29 November 2017

1 reference

Wei Lemaire

1 reference

29 November 2017

Julie A O'Brien

1 reference

29 November 2017

Maryann Burno

1 reference

29 November 2017

Ashok G Chaudhary

1 reference

29 November 2017

Dennis C Dean

1 reference

29 November 2017

Peter D Williams

1 reference

29 November 2017

Roger M Freidinger

1 reference

29 November 2017

Douglas J Pettibone

1 reference

29 November 2017

David L Williams

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

European Journal of Pharmacology

29 November 2017

published in

1 reference

29 November 2017

volume

450

1 reference

29 November 2017

1 reference

29 November 2017

page(s)

19-28

1 reference

Central functions of oxytocin

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Vasopressin and oxytocin receptors in the central nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Molecular cloning of the receptor for human antidiuretic hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Cloning and characterization of the human V3 pituitary vasopressin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Central nervous system effects of the neurohypophyseal hormones and related peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Oxytocin receptors in nonpregnant human uterus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

The oxytocin receptor system: structure, function, and regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Structure and expression of a human oxytocin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response t

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Molecular cloning and expression of a rat V1a arginine vasopressin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Cloning and expression of the rhesus monkey oxytocin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Alpha 2-adrenoceptor coupling to adenylate cyclase in adrenaline insensitive human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

The brain oxytocin receptor(s)?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902048-4

10.1016/S0014-2999(02)02048-4

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference